Genesis Molecular AI vs Iktos (2026)
Two generative chemistry companies with different commercial shapes. Genesis is a research lineage platform integrating language models, diffusion and physics for small molecule discovery. Iktos has been at generative medicinal chemistry since 2016 and sells both ways, as licensed software and as a discovery collaboration, which gives a pharmaceutical buyer a route in that does not require handing over the programme. That optionality matters more than it sounds, because most partnerships in this category start as evaluations and stall when the customer wants to keep the work in house. Neither can be compared on published evidence in the way a buyer would like, since the meaningful output is a molecule that works and that takes years. Ask both how many designed molecules were actually synthesised and tested, because a design that cannot be made is a delay rather than a discovery.
- The platform integrates language models, diffusion and physics into small molecule discovery from a research lineage rather than assembling tools around a services business.
- Generative chemistry with a stated technical approach lets a medicinal chemistry team evaluate the method rather than the demonstration.
- For a partner wanting molecule design capability, a focused discovery platform is a different purchase from a broader services relationship.
- It sells both as software and as discovery collaboration, so a pharmaceutical team can license the tools or hand over the programme depending on internal capacity.
- Nearly a decade of operating history in generative medicinal chemistry means the workflow has met real programmes rather than benchmark tasks.
- The dual commercial model gives a buyer an exit from a services relationship into a licence, which is rare in this category.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Genesis Molecular AI and Iktos are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Genesis Molecular AI | Iktos |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | 2016 |
| Headquarters | Burlingame, CA | Paris, France |
| Website | genesis.ml | iktos.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Genesis Molecular AI its top capability grade on AI Centrality. Set against Iktos, Genesis Molecular AI does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Iktos its top capability grade on AI Centrality and Deployment Model and Data Residency. Set against Genesis Molecular AI, Iktos grades higher on several axes, including FDA and Regulatory Status, AI Governance and Bias Disclosure and Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Genesis Molecular AI or Iktos?
The AI Health Index grades Iktos higher than Genesis Molecular AI on every axis that separates them, several axes, including FDA and Regulatory Status, AI Governance and Bias Disclosure and Deployment Model and Data Residency. Genesis Molecular AI does not grade higher on any scored axis.
Where do Genesis Molecular AI and Iktos differ most?
The widest separation the AI Health Index records between Genesis Molecular AI and Iktos is on Deployment Model and Data Residency, where Genesis Molecular AI grades C and Iktos grades A. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do Genesis Molecular AI and Iktos grade the same?
The AI Health Index grades Genesis Molecular AI and Iktos the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Generative chemistry platforms are almost impossible to compare on published evidence because the meaningful output is a molecule that works, which takes years, and everything before that is benchmark performance on tasks the vendor selected. Ask both for programmes that reached a development candidate and what proportion of designed molecules were synthesised and tested, since a design tool that proposes what cannot be made is a slower path rather than a faster one. Neither publishes a security attestation. Neither publishes pricing, and the software against collaboration distinction changes the commercial comparison entirely.